A phase II, open-label, multi-center study to assess pharmacokinetics (PK), safety and efficacy of POL7080 co-administered with standard of care (SoC) treatment in patients with ventilator- associated pneumonia (VAP) due to suspected or documented Pseudomonas aeruginosa infection
Latest Information Update: 07 Nov 2021
At a glance
- Drugs Murepavadin (Primary)
- Indications Pseudomonal infections; Ventilator associated pneumonia
- Focus Pharmacokinetics
- Sponsors Polyphor
- 26 Apr 2021 This trial has been discontinued in Spain (End Date: 02 Dec 2015), according to European Clinical Trials Database record.
- 25 Apr 2017 Results assessing PK and efficacy, presented at the 27th European Congress of Clinical Microbiology and Infectious Diseases
- 12 Apr 2016 Interim results (n=10) presented at the 26th European Congress of Clinical Microbiology and Infectious Diseases